论文部分内容阅读
目的研究老年脑梗死患者应用阿伦膦酸钠维D3与钙剂等骨质疏松干预治疗前后骨密度、骨生化与转换相关指标变化。方法应用骨密度仪对受试者足踝部进行骨密度(BMD)测定。应用偶氮胂Ⅲ法检测血钙与钼酸盐法检测血磷,应用双抗体夹心法检测人25羟基维生素D3[25(OH)D3]、甲状旁腺素(PTH)、骨钙素(BGP)、1型胶原羧基末端肽(β-CTX)、1型前胶原氨基端肽(P1NP)、骨源性碱性磷酸酶(BALP)。结果干预组患者干预前后除血Ca2+、血P3+分别互相比较无统计学差异(t=1.430,1.528,P>0.05)外,25(OH)D3、PTH、BGP、P1NP、BALP与β-CTX分别互相比较均有统计学差异(t=-25.964,-3.441,-3.079,-2.074,4.182,5.149,P<0.05)。结论对老年脑梗死急性期后伴肢体瘫痪患者在常规应用脑梗死药物治疗基础上,进行肢体康复治疗同时给予阿伦膦酸钠维D3与钙剂等骨质疏松干预治疗,对促进骨形成和抑制骨吸收有一定作用。
Objective To study the changes of bone mineral density (BMD), bone biochemistry and the related indexes before and after treatment with osteoporosis such as alendronate sodium and vitamin D3 in elderly patients with cerebral infarction. Methods Bone mineral density (BMD) measurements were performed on the ankle and foot of the subjects. Application of arsenazo Ⅲ method to detect blood calcium and molybdate method for the detection of serum phosphorus, double antibody sandwich method for the detection of human 25 hydroxy vitamin D3 [25 (OH) D3], parathyroid hormone (PTH), osteocalcin (BGP ), Type 1 collagen carboxyl terminal peptide (β-CTX), type 1 procollagen amino terminal peptide (P1NP) and bone alkaline phosphatase (BALP). Results The levels of 25 (OH) D3, PTH, BGP, P1NP, BALP and β-CTX in the intervention group before and after intervention were significantly lower than those in the control group (t = 1.430,1.528, P> 0.05) Compared with each other statistically significant differences (t = -25.964, -3.441, -3.079, -2.074,4.182,5.149, P <0.05). Conclusion After acute cerebral infarction with limb paralysis in patients with conventional cerebral infarction on the basis of drug treatment, limb rehabilitation treatment given at the same time alendronate sodium and calcium D3 and other osteoporosis interventions, to promote bone formation and Inhibit bone resorption has a certain effect.